Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study

Published:2021-09 Issue: Volume:Volume 15 Page:3787-3795
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Chakraborty Debdulal^ORCID,Maiti Aniruddha,Sheth Jay U^ORCID,Boral Subhendu,Mondal Soumen,Nandi Krishnendu,Sinha Tushar,Das Arnab

Publisher

Informa UK Limited

Reference30 articles.

1. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept

2. The Impact of Anti–Vascular Endothelial Growth Factor Treatment on Quality of Life in Neovascular Age-Related Macular Degeneration

3. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti–VEGF Drug Type for 1 Year in the IRIS Registry

4. Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration

5. Anti-VEGF Therapy for Retinal Vein Occlusions

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review;Medicine;2025-06-06

2. Faricimab Outcomes in Chorioretinal Disorders: Indian Real-World Analysis (FOCUS Study);Clinical Ophthalmology;2025-06

3. Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study;Ophthalmology and Therapy;2025-05-28

4. Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India;Indian Journal of Ophthalmology;2025-04-17

5. Proactive Post-Injection Monitoring in Brolucizumab Therapy: A Study on Intraocular Inflammation and Treatment Outcomes;Clinical Ophthalmology;2025-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.7亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3